Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

Trial ID: NCT05781711

Interventional - Phase 2 - Completed

Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in PD

Conditions

• Parkinson Disease

Interventions

• levodopa-carbidopa
• Metformin

Eligibility

Inclusion criteria

• Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa

Exclusion criteria

• Secondary causes of Parkinsonism Diabetic patients Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Suffering from active malignancy Addiction to alcohol and/or drugs Known allergy to the studied medications

Sponsor

Tanta University, Menoufia University

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows